Focused On-demand Library for N-alpha-acetyltransferase 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P41227

UPID:

NAA10_HUMAN

Alternative names:

N-terminal acetyltransferase complex ARD1 subunit homolog A; NatA catalytic subunit Naa10

Alternative UPACC:

P41227; A6NM98

Background:

N-alpha-acetyltransferase 10, known as Naa10, plays a pivotal role in protein synthesis and function. It acts as the catalytic subunit of N-terminal acetyltransferase complexes, modifying proteins by acetylating their amino termini. This modification is crucial for various biological processes, including vascular, hematopoietic, and neuronal growth and development. Naa10's ability to acetylate and stabilize key proteins like TSC2 and HSPA1A enhances its significance in cellular homeostasis and stress response.

Therapeutic significance:

Naa10's involvement in diseases such as N-terminal acetyltransferase deficiency and Microphthalmia, syndromic, 1, underscores its therapeutic potential. By understanding Naa10's role in these conditions, researchers can develop targeted therapies to modulate its activity. This could lead to innovative treatments for these genetic disorders, offering hope for affected individuals.